Categories
  • Biopharmaceutical companies
  • Companies listed on the Nasdaq
  • 2014 initial public offerings
    •   Encyclosphere.org ENCYCLOREADER
      supported by EncyclosphereKSF

    Lundbeck Seattle Biopharmaceuticals

    From Wikipedia - Reading time: 4 min
    Lundbeck Seattle Biopharmaceuticals
    FormerlyAlder Biopharmaceuticals
    TypeSubsidiary
    Founded1 January 2004 Edit this on Wikidata
    Headquarters
    Bothell, Washington
    ,
    U.S.
    ParentLundbeck
    Websitehttps://www.lundbeck.com/us/about-us/lundbeck-in-the-us

    Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies.

    In May 2014, Alder went public.[1] In early 2018, the company made a public stock offering, aiming to raise US$250 million.[2] The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas.[3]

    As of September 2019, the Alder Biopharmaceuticals shares have increased with 83% in price, following the company's acquisition by the Denmark-based H. Lundbeck, in a deal valued at $1.95 billion.[4][5] The company subsequently changed its name to Lundbeck Seattle Biopharmaceuticals after the acquisition.[6]

    References[edit]

    1. ^ "Alder BioPharmaceuticals stock flat after unexciting IPO". geekwire.com. 8 May 2014. Retrieved 24 August 2017.
    2. ^ "Deals this week: Onconova Therapeutics, Humorigin Biotechnology, Zosano Pharma". Drug Development Technology. Kable. 2 February 2018. Retrieved 3 February 2018.
    3. ^ "Alder Biopharmaceuticals Inc - Company Profile and News". Bloomberg.com. Retrieved 2019-05-21.
    4. ^ Kilgore, Tomi (2019-09-16). "Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal". Market Watch. Retrieved 2019-10-21.{{cite web}}: CS1 maint: url-status (link)
    5. ^ staff, Seattle Times business (2019-09-16). "Alder BioPharma, Bothell developer of migraine-prevention drug, acquired for up to $2 billion". The Seattle Times. Retrieved 2020-06-18. {{cite web}}: |first= has generic name (help)
    6. ^ Podsada, Janice (August 5, 2020). "Bay Area bio-tech firm to open production plant in Bothell". The Everett Herald. Retrieved February 19, 2022.
    Stub icon

    This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

    • v
    • t
    • e
    This article is licensed under CC BY-SA 3.0.
    Original source: https://en.wikipedia.org/wiki/Lundbeck Seattle Biopharmaceuticals
    Status: article is cached
    Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF